LUCY vs PRPH

For growth investors, Innovative Eyewear, Inc.

(LUCY) is the stronger pick with 42. 0% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ProPhase Labs, Inc.

(PRPH) delivered a total return of -63. 2%, compared to -99. 1% for Innovative Eyewear, Inc. (LUCY). Over 10 years, the gap is even starker: PRPH returned +37. 5% versus LUCY's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innovative Eyewear, Inc.

(LUCY) is the lower-risk stock at 1. 52β versus ProPhase Labs, Inc. 's 2. 28β — meaning PRPH is approximately 50% more volatile than LUCY relative to the S&P 500.

By revenue growth (latest reported year), Innovative Eyewear, Inc.

(LUCY) is pulling ahead at 42. 0% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Innovative Eyewear, Inc. grew EPS 59. 0% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, LUCY leads at 33. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innovative Eyewear, Inc.

(LUCY) is the more profitable company, earning -474. 6% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps -474. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LUCY leads at -484. 2% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — LUCY leads at 13. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innovative Eyewear, Inc.

(LUCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. ProPhase Labs, Inc. (PRPH) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LUCY: -99. 1%, PRPH: +37. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LUCY is a small-cap high-growth stock; PRPH is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.